https://www.technologynetworks.com/drug-discovery/news/pierre-fabre-pharmaceuticals-and-addex-sign-earlystage-agreement-205402
Addex grants option to license mGlu3 receptor program to Pierre Fabre Pharmaceuticals.
pierre fabreearly stagepharmaceuticalssignagreement
https://www.technologynetworks.com/cancer-research/news/smarce1-linked-to-aggressive-early-stage-breast-cancer-287121
Findings make it possible to distinguish poorly invasive tumors from those that will likely spread and metastasize.
early stagebreast cancerlinkedaggressivetechnology